Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial
-
- Elena Santagostino
- Istituto di Ricovero e Cura a Carattere Scientifico Ca’ Granda Foundation, Maggiore Hospital Policlinico, Milan, Italy;
-
- Uri Martinowitz
- The Israeli National Haemophilia Center, Chaim Sheba Medical Center, Tel Hashomer, Israel;
-
- Toshko Lissitchkov
- Department of Coagulation Disorders and Anemia, Specialized Hospital for Active Treatment Joan Pavel, Sofia, Bulgaria;
-
- Brigitte Pan-Petesch
- Centre Hospitalier Régional Universitaire de Brest, Hôpital A. Morvan, Brest, France;
-
- Hideji Hanabusa
- Department of Hematology, Ogikubo Hospital, Tokyo, Japan;
-
- Johannes Oldenburg
- Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany;
-
- Lisa Boggio
- Rush Hemophilia and Thrombophilia Center, Rush University, Chicago, IL;
-
- Claude Negrier
- Centre Régional de Traitement de l’Hémophilie, Hôpital Edouard Herriot, University Claude Bernard, Lyon, France;
-
- Ingrid Pabinger
- Division of Haematology and Haemostaseology, Medical University of Vienna, Vienna, Austria;
-
- Mario von Depka Prondzinski
- Werlhof Institut, Hannover, Germany;
-
- Carmen Altisent
- Unitat Hemofilia, Hospital Vall d’Hebron, Barcelona, Spain;
-
- Giancarlo Castaman
- Haemophilia and Thrombosis Centre, Department of Haematology, San Bortolo Hospital, Vicenza, Italy;
-
- Koji Yamamoto
- Nagoya University Hospital, Nagoya, Japan;
-
- Maria-Teresa Álvarez-Roman
- Hospital la Paz, Madrid, Spain; and
-
- Christine Voigt
- Clinical Research and Development, CSL Behring, King of Prussia, PA
-
- Nicole Blackman
- Clinical Research and Development, CSL Behring, King of Prussia, PA
-
- Iris Jacobs
- Clinical Research and Development, CSL Behring, King of Prussia, PA
Description
<jats:title>Key Points</jats:title> <jats:p>rIX-FP maintains mean trough of 20 and 12 IU/dL FIX activity with 40 IU/kg weekly and 75 IU/kg every 2 weeks prophylaxis, respectively. Weekly and 14-day prophylaxis regimens with rIX-FP were well tolerated and provided low bleeding rates and target joint improvement.</jats:p>
Journal
-
- Blood
-
Blood 127 (14), 1761-1769, 2016-04-07
American Society of Hematology
- Tweet
Details 詳細情報について
-
- CRID
- 1360567186713712640
-
- ISSN
- 15280020
- 00064971
-
- Data Source
-
- Crossref
- KAKEN